Bell Max, Granath Fredrik, Schön Staffan, Löfberg Erland, Ekbom Anders, Martling Claes-Roland
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Crit Care Med. 2008 Oct;36(10):2773-8. doi: 10.1097/CCM.0b013e318187815a.
OBJECTIVE: The number of patients with end-stage renal disease has increased during the last decades. Data shows that 10% of the renal replacement therapy population in the intensive care unit are patients with end-stage renal disease. We aimed to describe the short- and long-term outcome of these patients after renal replacement therapy in the intensive care unit. DESIGN: Nationwide cohort study between the years 1995 and 2004. Follow-up up to 5 years. SETTING: Swedish general intensive care units and Swedish hospitals. PATIENTS: Eligible subjects were end-stage renal disease patients treated with renal replacement therapy in 32 Swedish general intensive care units. In total, 245 patients were studied. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Short- and long-term mortality was studied. Logistic regression was used to analyze short-term mortality. Long-term mortality was compared with the mortality of end-stage renal disease patients outside the intensive care unit and the mortality in the population. Diabetes and heart failure are significant risk factors for 90-day mortality, with an odds ratio of 1.9 and 2.0, respectively. The intensive care unit end-stage renal disease cohort had increased long-term mortality as compared with non-intensive care unit end-stage renal disease patients, relative risk of death 2.32 (confidence interval 1.84-2.92). A comparison with the mortality rate in the general population yielded a standardized mortality ratio of 25 (95% confidence interval: 19.6-31.4). CONCLUSIONS: For end-stage renal disease patients in the intensive care unit, age, diabetes mellitus, and heart failure are risk factors for 90-day mortality. Long-term mortality is associated with age and heart failure. The long-term mortality of end-stage renal disease patients surviving the intensive care unit stay is significantly higher compared with end-stage renal disease patients without a known intensive care unit admission.
目的:在过去几十年中,终末期肾病患者的数量有所增加。数据显示,重症监护病房中接受肾脏替代治疗的患者群体中有10%是终末期肾病患者。我们旨在描述这些患者在重症监护病房接受肾脏替代治疗后的短期和长期结局。 设计:1995年至2004年的全国性队列研究。随访长达5年。 地点:瑞典普通重症监护病房和瑞典医院。 患者:符合条件的受试者是在32个瑞典普通重症监护病房接受肾脏替代治疗的终末期肾病患者。总共研究了245名患者。 干预措施:无。 测量指标和主要结果:研究了短期和长期死亡率。采用逻辑回归分析短期死亡率。将长期死亡率与重症监护病房外的终末期肾病患者死亡率以及总体人群死亡率进行比较。糖尿病和心力衰竭是90天死亡率的重要危险因素,比值比分别为1.9和2.0。与非重症监护病房的终末期肾病患者相比,重症监护病房的终末期肾病队列长期死亡率有所增加,死亡相对风险为2.32(置信区间1.84 - 2.92)。与总体人群死亡率进行比较得出标准化死亡率为25(95%置信区间:19.6 - 31.4)。 结论:对于重症监护病房中的终末期肾病患者,年龄、糖尿病和心力衰竭是90天死亡率的危险因素。长期死亡率与年龄和心力衰竭有关。与未入住过重症监护病房的终末期肾病患者相比,在重症监护病房存活下来后的终末期肾病患者长期死亡率显著更高。
Crit Care Med. 2010-1
Nephrol Dial Transplant. 2008-6
Kidney Int Rep. 2024-10-28
Crit Care. 2023-9-18
Arch Med Sci Atheroscler Dis. 2016-5-5
Intensive Care Med. 2015-11-25